The present invention relates to stabilized radiopharmaceutical compositions comprising a F-18 radiolabelled compound and at least one stabilizer against radiolytic degradation. The disclosed compositions are free from cyclodextrin or derivatives thereof and in some embodiments are also free from ascorbic acid and its salts. More specifically, the present invention provides compositions comprising Flurpiridaz F-18 for myocardial perfusion imaging, with desirable technical attributes of purity, radiochemical purity, physical and chemical stability and shelf-life, comprising at least one stabilizer against radiolytic degradation and optionally a co-solvent or solubilizing agent wherein the compositions are free from cyclodextrin or derivatives thereof.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
2.
FLUORINE-18 RADIOPHARMACEUTICAL COMPOSITIONS FOR PET IMAGING
The present invention relates to stabilized radiopharmaceutical compositions comprising a F-18 radiolabelled compound and at least one stabilizer against radiolytic degradation. The disclosed compositions are free from cyclodextrin or derivatives thereof and in some embodiments are also free from ascorbic acid and its salts. More specifically, the present invention provides compositions comprising Flurpiridaz F-18 for myocardial perfusion imaging, with desirable technical attributes of purity, radiochemical purity, physical and chemical stability and shelf-life, comprising at least one stabilizer against radiolytic degradation and optionally a co-solvent or solubilizing agent wherein the compositions are free from cyclodextrin or derivatives thereof.
G01T 1/29 - Mesure effectuée sur des faisceaux de radiations, p. ex. sur la position ou la section du faisceauMesure de la distribution spatiale de radiations
3.
RADIOLABELED STYRYLPYRIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF
The invention discloses radiopharmaceutical composition of Fluorine-18 (F18) labelled styrylpyridine compounds, for use as a medicament for the treatment or diagnosis of a disease or condition associated with build-up of amyloid-β (Aβ) aggregates, preferably F18 Florbetapir, that is free of undesirable nitrosamine drug substance related impurities (NDSRI) and other undesirable nitrosamine impurities. The invention further relates to polymorphic forms of precursors of F18 Florbetapir and their use for preparing F18 Florbetapir.
The present disclosure relates in general to nuclear medicine and generators for the production of radiopharmaceuticals for medical use. In particular, present disclosure relates to a generator column that resists high heat such as depyrogenation and sterilization. This allows some steps of the preparation of the column to be performed in a non-sterile environment. This also allows the generator column to be reusable. The present disclosure further describes methods for the preparation of a generator where a parent radioisotope is charged on the column matrix before or after the matrix is loaded in the column.
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
G21G 4/08 - Sources radioactives autres que les sources de neutrons caractérisées par des aspects de leur structure spécialement adaptées aux applications médicales
5.
ALBUMIN CONJUGATES AND PROCESS FOR PREPARATION THEREOF
The embodiments of the present invention disclose a conjugate compound of formula X-J-MAA, wherein X is a diagnostic or therapeutic radioisotope; J is an optional chelating agent; and MAA is macroaggregated albumin particles. The invention also discloses sterile and stable ready to use or reconstituted radiopharmaceutical composition of X-J-MAA and manufacturing process thereof, preferably the invention relates to radiopharmaceutical compositions of 99mTc. The prepared radiopharmaceutical compositions exhibit desirable technical attributes like stability, radiochemical purity, less impurities, pH, better bio-distribution and desirable average particle size for further administration to patients for therapeutic and diagnostic use.
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
A61B 6/40 - Agencements pour générer des radiations spécialement adaptés au diagnostic par radiations
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 31/175 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine ayant le groupe , N-C(O)-N=N- ou , p. ex. carbonohydrazides, carbazones, semicarbazides, semicarbazonesLeurs thio-analogues
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/475 - QuinoléinesIsoquinoléines ayant un cycle indole, p. ex. yohimbine, réserpine, strychnine, vinblastine
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Artificial intelligence software for positron emission
tomography (PET) imaging; AI-enabled algorithm for positron
emission tomography (PET) imaging. Software as a service (SaaS) services offering software
utilizing artificial intelligence to assist in performing
pharmacokinetic modelling of positron emission tomography
(PET) imaging and quantifying output results; algorithm
utilizing artificial intelligence to assist in performing
pharmacokinetic modelling of positron emission tomography
(PET) imaging and quantifying output results, such as
myocardial blood flow (MBF).
7.
PHARMACEUTICAL COMPOSITION COMPRISING TETROFOSMIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
The present invention relates to a stable pharmaceutical composition of tetrofosmin or pharmaceutically acceptable salts thereof. It also relates to a lyophilized non-radioactive kit which upon reconstitution with 99mTc-pertechnetate solution gives a stable 99mTc-tetrofosmin radiopharmaceutical composition. It also provides process for the preparation of said radiopharmaceutical compositions and their use in diagnostic imaging procedures. The compositions provide desirable technical attributes such as stability, purity, high radiochemical purity (RCP) and desired bio-distribution. The composition comprises less than 1% w/w dioxo tetrofosmin (TFS-2) content and less than 1% w/w mono-oxo tetrofosmin content.
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Artificial intelligence software for positron emission tomography (PET) imaging; AI-enabled algorithm for positron emission tomography (PET) imaging. Software as a service (SaaS) services offering software utilizing artificial intelligence to assist in performing pharmacokinetic modelling of positron emission tomography (PET) imaging and quantifying output results; algorithm utilizing artificial intelligence to assist in performing pharmacokinetic modelling of positron emission tomography (PET) imaging and quantifying output results, such as myocardial blood flow (MBF).
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Artificial intelligence software for positron emission tomography (PET) imaging; AI-enabled algorithm for positron emission tomography (PET) imaging (1) Software as a service (SaaS) services offering software utilizing artificial intelligence to assist in performing pharmacokinetic modelling of positron emission tomography (PET) imaging and quantifying output results; algorithm utilizing artificial intelligence to assist in performing pharmacokinetic modelling of positron emission tomography (PET) imaging and quantifying output results, such as myocardial blood flow (MBF)
Ottawa Heart Institute Research Corporation (Canada)
Inventeur(s)
Lefort, Etienne
Teoli, Vicenzo
Dekemp, Robert A.
Klein, Ran
Abrégé
Embodiments of the present invention provide for assessing the state of an 82Rb elution system. In certain embodiments, a system begins an assessment that comprises an elution, and a metric may be measured. This metric may be a concentration of 82Rb, 82Sr, or 85Sr in a fluid that is eluted from the generator, the volume of the fluid that is eluted from the generator, or the pressure of the fluid flowing through at least one portion of the system. If the assessment is completed, an output may be generated on a user interface that recommends a course of action, or no course of action, based on a result of the assessment. Should the assessment not complete successfully because it is interrupted, a 82Sr/82Rb generator of the system may be halted so as to prevent a user from performing an end-run around these quality control mechanisms of the 82Rb elution system.
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
The invention discloses radiopharmaceutical composition of Fluorine-18 (F18) labelled styrylpyridine compounds, preferably F18 Florbetapir, free of undesirable nitrosamine drug substance related impurities (NDSRI) and other undesirable impurities. The prepared radiopharmaceutical composition is used as a medicament for the treatment or diagnosis of a disease or condition associated with build-up of amyloid-β (Aβ) aggregates.
The invention discloses to radiopharmaceutical composition of Fluorine-18 (F18) labelled styrylpyridine compounds, preferably F18 Florbetapir, that are free of undesirable nitrosamine drug substance related impurities (NDSRI) and other undesirable nitrosamine impurities. The disclosed radiopharmaceutical composition is used as a medicament for the treatment or diagnosis of a disease or condition associated with build-up of amyloid-β (Aβ) aggregates.
The invention discloses radiopharmaceutical composition of Fluorine-18 (F18) labelled styrylpyridine compounds, for use as a medicament for the treatment or diagnosis of a disease or condition associated with build-up of amyloid-β (Aβ) aggregates. The invention further relates to polymorphic forms of precursors of F18 Florbetapir and their use for preparing F18 Florbetapir.
The present invention relates to a medical radioisotope transport system that securely holds the radiopharmaceutical imaging system or medical elution system to the floor of a vehicle and ensures the protection of the elution system during transportation. More particularly, the present invention relates to a mobile adaptation kit, comprising a floor frame assembly installed in a transport vehicle configured to support a mobile medical radioisotope elution system; and a T-bar that slides inside and out of the floor frame assembly, wherein the T-bar comprises a gasket and nylon sheets. The floor frame assembly comprises a floor frame that is installed and remains within the vehicle or van; a floor frame cover; an angled rail; a pivoting piece; a quick-release pin with a high-capacity pin that locks one end of the T-bar in place with the floor frame; and a locking mechanism, in order to safely and securely transport radiopharmaceuticals and medical imaging system, ensuring compliance to the regulatory and quality requirements. The transport system is easy to use and addresses the complexities involved in prior available methods for transportation of radiopharmaceutical imaging systems or medical radioisotope elution systems.
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
15.
ALBUMIN CONJUGATES AND RADIOPHARMACEUTICAL COMPOSITIONS THEREOF
The present invention discloses methods for automatically computing an arterial input function from one or more regions of interest, the method comprising: a. obtaining a plurality of dynamic image data sets comprising volumetric image data from the regions of interest over multiple scanning intervals; b. utilizing an artificial neural network to segment the plurality of dynamic image data sets displaying one or more arterial input function(s) (AIF) in the region(s) of interest; c. automatically estimating, using artificial intelligence, an arterial input function based on plurality of dynamic image data sets combined with one or more time activity curves (TAC) in the region(s) of interest in target organ(s); and d. computing a pre-trained predictive pharmacokinetic AI model arterial input function using time activity curve input associated with region(s) of interest of target organ(s).
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
A61B 6/50 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des parties du corps spécifiquesAppareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des applications cliniques spécifiques
G06T 7/62 - Analyse des attributs géométriques de la superficie, du périmètre, du diamètre ou du volume
18.
IMAGING METHOD FOR DIAGNOSING CARDIOVASCULAR DISEASE
The invention provides an image processing method to assess quantitative myocardial blood flow and/or myocardial flow reserve, comprising the steps of: (a) pre-processing of images comprises: (i) reconstructing dynamic cine 3D tomographic myocardial perfusion imaging (MPI) data, (ii) optionally, denoising to improve the quality of image, (iii) extracting blood input function from a region of interest (ROI) of the left ventricle blood cavity, (iv) estimating the distribution volume (DV), given by the ratio of uptake and washout rates (K1/k2) to stabilize and improve estimation of K1, k2 and total blood volume (TBV) and subsequent myocardial blood flow measures, and (v) data normalization by dividing by the maximum of the blood input function; (b) assessing the individual signals pre-processed in step (a) to generate K1 and TBV parametric maps using artificial neural network; (c) post-processing of K1, k2 and TBV parametric maps; and of rest and stress myocardial blood flow to estimate myocardial flow reserve (MFR) and/or coronary flow reserve (CFR).
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
A61B 6/50 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des parties du corps spécifiquesAppareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des applications cliniques spécifiques
G06V 10/25 - Détermination d’une région d’intérêt [ROI] ou d’un volume d’intérêt [VOI]
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
Ottawa Heart Institute Research Corporation (Canada)
Inventeur(s)
Lefort, Etienne
Teoli, Vincenzo
Dekemp, Robert A.
Klein, Ran
Abrégé
Provided are 82Sr/82Rb elution systems that accept patient weight as a input function in order to determine an optimal quantity of radioactive rubidium-82 for delivery to a patient pursuant to an imaging scan. Also disclosed are systems that deliver a saline flush to remove residual 82Rb from the system downstream of the generator, and preferably deliver the removed residual 82Rb to the patient. Other disclosed systems measure the total volume of saline that flows through a 82Sr/82Rb generator, a total volume of saline that flows through the generator and through a bypass line, or a total volume of saline received by a waste reservoir, in order to monitor system components so that optimal system functioning is assured.
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
G16H 20/40 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mécaniques, la radiothérapie ou des thérapies invasives, p. ex. la chirurgie, la thérapie laser, la dialyse ou l’acuponcture
20.
Radiopharmaceutical delivery system for patient infusion
The present invention relates to a theranostic delivery system or radiopharmaceutical drugs delivery system (100) with movable ergonomic workstation (3) having handles on the side(s) to move the cart. The radiopharmaceutical drugs delivery system (100) comprises of simple design and multiple enhanced safety features for user. The delivery system (100) includes a disposable secondary containment system (2) that protect the core workstation from contamination, a configurable dose transporter (6) that allows for safe transport of the hot dose between the hot lab to the infusion site and a disposable sealed fluid cartridge (7) to withdraw custom volume from the vial or syringe. The delivery system (100) comprises a theranostic informatics management system with a computer screen (19) as graphical user interface (GUI) with retractable rotating arm (20) to receive the various patient infusion parameters and effectively manage delivery of desired dose to patient.
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
The present disclosure concerns radiopharmaceutical compositions of radioactive halogenated benzylguanidine (such as radioiodinated MIBG) or a pharmaceutically acceptable salt, hydrate, or solvate thereof. In a preferred embodiment, the composition has at least 97% of radiochemical purity for at least 4 days. Advantageously, the compositions of the present disclosure may be devoid of parabens, which are carcinogenic and yet are used in known radioactive MIBG compositions. The present disclosure also provides processes of preparing a radioactive halogenated benzylguanidine composition. The compositions of the present disclosure can be used in diagnosis and treatment of various diseases.
The embodiments of the present invention disclose a conjugate compound of formula X-J- MAA, wherein X is a diagnostic or therapeutic radioisotope; J is an optional chelating agent; and MAA is macroaggregated albumin particles. The invention also discloses sterile and stable ready to use or reconstituted radiopharmaceutical composition of X-J-MAA and manufacturing process thereof. The prepared radiopharmaceutical compositions exhibit desirable technical attributes like stability, radiochemical purity, less impurities, pH, better bio-distribution and desirable average particle size for further administration to patients for therapeutic and diagnostic use
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
The embodiments of the present invention disclose a conjugate compound of formula X-J- MAA, wherein X is a diagnostic or therapeutic radioisotope; J is an optional chelating agent; and MAA is macroaggregated albumin particles. The invention also discloses sterile and stable ready to use or reconstituted radiopharmaceutical composition of X-J-MAA and manufacturing process thereof. Preferably, the invention relates to radiopharmaceutical compositions of 99mTc. The prepared radiopharmaceutical compositions exhibit desirable technical attributes like stability, radiochemical purity, less impurities, pH, better bio- distribution and desirable average particle size for further administration to patients for therapeutic and diagnostic use.
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
The embodiments of the present invention disclose a conjugate compound of formula X-J-MAA, wherein X is a diagnostic or therapeutic radioisotope; J is an optional chelating agent; and MAA is macroaggregated albumin particles. The invention also discloses sterile and stable ready to use or reconstituted radiopharmaceutical composition of X-J-MAA and manufacturing process thereof. The prepared radiopharmaceutical compositions exhibit desirable technical attributes like stability, radiochemical purity, less impurities, pH, better bio-distribution and desirable average particle size for further administration to patients for therapeutic and diagnostic use.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/175 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine ayant le groupe , N-C(O)-N=N- ou , p. ex. carbonohydrazides, carbazones, semicarbazides, semicarbazonesLeurs thio-analogues
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/475 - QuinoléinesIsoquinoléines ayant un cycle indole, p. ex. yohimbine, réserpine, strychnine, vinblastine
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
The embodiments of the present invention disclose a conjugate compound of formula X-J-MAA, wherein X is a diagnostic or therapeutic radioisotope; J is an optional chelating agent; and MAA is macroaggregated albumin particles. The invention also discloses sterile and stable ready to use or reconstituted radiopharmaceutical composition of X-J-MAA and manufacturing process thereof, preferably the invention relates to radiopharmaceutical compositions of 99mTc. The prepared radiopharmaceutical compositions exhibit desirable technical attributes like stability, radiochemical purity, less impurities, pH, better bio-distribution and desirable average particle size for further administration to patients for therapeutic and diagnostic use.
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
The present invention relates to a pharmaceutical cold kit composition comprising a chelating agent linked to somatostatin receptor binding organic moiety, a stabilizer, a buffer, and a caking agent or bulking agent, wherein the composition is free of sequestering agent. Further, the present invention also relates to the process of preparing reconstituted or radiolabeled solution composition having high in use stability and radiochemical purity and use thereof for diagnostic and/or therapeutic purposes.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
The present invention describes methods and techniques to improve scintigraphic images obtained by using nuclear medicine techniques for diagnostic analysis. The present invention describes a method and technique to up-sample and down-sample nuclear medicine images that models photon counts and noise characteristics of an image at its target resolution.
G06T 3/4007 - Changement d'échelle d’images complètes ou de parties d’image, p. ex. agrandissement ou rétrécissement basé sur l’interpolation, p. ex. interpolation bilinéaire
29.
METHODS AND TECHNIQUES OF RESIZING OF SCINTIGRAPHY IMAGES
The present invention describes methods and techniques to improve scintigraphic images obtained by using nuclear medicine techniques for diagnostic analysis. The present invention describes a method and technique to up-sample and down-sample nuclear medicine images that models photon counts and noise characteristics of an image at its target resolution.
G06T 3/4007 - Changement d'échelle d’images complètes ou de parties d’image, p. ex. agrandissement ou rétrécissement basé sur l’interpolation, p. ex. interpolation bilinéaire
G06T 3/4007 - Changement d'échelle d’images complètes ou de parties d’image, p. ex. agrandissement ou rétrécissement basé sur l’interpolation, p. ex. interpolation bilinéaire
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 30/00 - TIC spécialement adaptées au maniement ou au traitement d’images médicales
32.
QUALITY CONTROL SYSTEM FOR CARDIAC POSITRON EMISSION TOMOGRAPHY IMAGES
The present invention relates to a quality control system for generation of a concordance assessment of medical imaging data from the medical imaging unit, the infusion profile data from the infusion profile data unit, and/or patient characteristic's data using a computer executable algorithm stored in memory. The quality control system comprises a data processing unit, a memory that stores computer executable algorithm, a medical imaging data unit, an infusion profile data unit, and patient characteristic's data. The data processing unit determines a concordance assessment of the data; wherein: a) the concordance assessment is generated by comparing the medical imaging data from the medical imaging unit, the infusion profile data from the infusion profile data unit, and the patient characteristic's data using a computer executable algorithm stored in memory; b) a user warning is generated for excessive mismatches between infusion profile data, imaging data, and/or patient characteristic's data; and c) the infusion profile data unit is Sr-Rb elution system infusion data.
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
33.
Radiopharmaceutical Compositions of Radioactive Halogenated Benzylguandine
The present disclosure concerns radiopharmaceutical compositions of radioactive halogenated benzylguanidine (such as radioiodinated MIBG) or a pharmaceutically acceptable salt, hydrate, or solvate thereof. In a preferred embodiment, the composition has at least 97% of radiochemical purity for at least 4 days. Advantageously, the compositions of the present disclosure may be devoid of parabens, which are carcinogenic and yet are used in known radioactive MIBG compositions. The present disclosure also provides processes of preparing a radioactive halogenated benzylguanidine composition. The compositions of the present disclosure can be used in diagnosis and treatment of various diseases.
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Artificial intelligence software for positron emission
tomography (PET) imaging; AI-enabled algorithm for positron
emission tomography (PET) imaging. Software as a service (SaaS) services offering software
utilizing artificial intelligence to assist in performing
pharmacokinetic modelling of positron emission tomography
(PET) imaging and quantifying output results; algorithm
utilizing artificial intelligence to assist in performing
pharmacokinetic modelling of positron emission tomography
(PET) imaging and quantifying output results, such as
myocardial blood flow (MBF).
35.
Radiopharmaceutical delivery system and use thereof for patient infusion
The invention is a theranostic delivery system or radiopharmaceutical drugs delivery system with movable workstation having handles. The workstation of theranostic delivery system or radiopharmaceutical drugs delivery system also has an on-board shielded disposal system for waste collection, which is operated by foot actuated system for locked and unlocked modes during the device journey. The theranostic delivery system or radiopharmaceutical drugs delivery system comprises a status light system that illuminates the working area to enable distance monitoring. Further, the delivery system includes a disposable secondary containment system that protects the core workstation from contamination, a configurable dose transporter and a disposable sealed fluid cartridge to withdraw custom volume from the vial or syringe. The delivery system includes a theranostic informatics management system, which contains a computer screen as a graphical user interface with a retractable rotating arm to receive the various patient infusion parameters.
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
36.
RADIOPHARMACEUTICAL DELIVERY SYSTEM FOR PATIENT INFUSION
A61M 36/06 - Dispositions spécialement adaptées pour introduire, p. ex. par inhalation ou par injection, un matériau radioactif dans le corps par injection d'un fluide contenant un agent radioactif ou un agent d'activation à travers un conduit pénétrant dans le corps en perçant la peau
A61M 36/08 - Blindage du réservoir de fluide, p. ex. blindage de seringue
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
37.
RADIOPHARMACEUTICAL CONJUGATE COMPOUND FOR DIAGNOSIS AND/OR THERAPEUTIC USES THEREOF
The present invention provides a conjugate compound comprising a nanoparticulated enhanced permeability and retention (EPR) agent, which is an albumin, conjugated with one or more chelating agents, one or more target specific ligands and one or more detectable agents and optionally comprising one or more heterobifunctional crosslinkers and one or more pharmaceutically acceptable therapeutic agents. Further, the present invention provides a radiopharmaceutical composition and a kit comprising the said conjugate and also provides application of the same in diagnosis and therapy of various disease like cancer.
The present invention provides a conjugate compound comprising a nanoparticulated enhanced permeability and retention (EPR) agent, which is an albumin, conjugated with one or more chelating agents, one or more target specific ligands and one or more detectable agents and optionally comprising one or more heterobifunctional crosslinkers and one or more pharmaceutically acceptable therapeutic agents. Further, the present invention provides a radiopharmaceutical composition and a kit comprising the said conjugate and also provides application of the same in diagnosis and therapy of various disease like cancer.
The present invention relates to a theranostic delivery system or radiopharmaceutical drugs delivery system (100) with movable ergonomic workstation (3) having handles on the side(s) to move the cart. The radiopharmaceutical drugs delivery system (100) comprises of simple design and multiple enhanced safety features for user. The delivery system (100) includes a disposable secondary containment system (2) that protect the core workstation from contamination, a configurable dose transporter (6) that allows for safe transport of the hot dose between the hot lab to the infusion site and a disposable sealed fluid cartridge (7) to withdraw custom volume from the vial or syringe. The delivery system (100) comprises a theranostic informatics management system with a computer screen (19) as graphical user interface (GUI) with retractable rotating arm (20) to receive the various patient infusion parameters and effectively manage delivery of desired dose to patient.
A61M 36/06 - Dispositions spécialement adaptées pour introduire, p. ex. par inhalation ou par injection, un matériau radioactif dans le corps par injection d'un fluide contenant un agent radioactif ou un agent d'activation à travers un conduit pénétrant dans le corps en perçant la peau
A61M 36/08 - Blindage du réservoir de fluide, p. ex. blindage de seringue
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
40.
Radiopharmaceutical delivery system and use thereof for patient infusion
The invention is a theranostic delivery system or radiopharmaceutical drugs delivery system with movable workstation having handles. The workstation of theranostic delivery system or radiopharmaceutical drugs delivery system also has an on-board shielded disposal system for waste collection, which is operated by foot actuated system for locked and unlocked modes during the device journey. The theranostic delivery system or radiopharmaceutical drugs delivery system comprises a status light system that illuminates the working area to enable distance monitoring. Further, the delivery system includes a disposable secondary containment system that protects the core workstation from contamination, a configurable dose transporter and a disposable sealed fluid cartridge to withdraw custom volume from the vial or syringe. The delivery system includes a theranostic informatics management system, which contains a computer screen as a graphical user interface with a retractable rotating arm to receive the various patient infusion parameters.
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
Disclosed are new configurations of a rubidium elution system that offer several advantages. The rubidium elution systems of the present disclosure comprise an assembly including a 82Sr/82Rb generator, an activity detector, a waste container, a pump, a sensor, a tubing circuit and at least one valve. The waste container is located in the lower section of the assembly. More particularly, the top surface of the waste container compartment is either below the top surface of the generator compartment, or the waste container is at the same elevation than the generator or below the pump.
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 5/145 - Perfusion sous pression, p. ex. utilisant des pompes utilisant des réservoirs sous pression, p. ex. au moyen de pistons
F04B 17/03 - Pompes caractérisées par leur combinaison avec des machines motrices ou moteurs particuliers qui les entraînent ou par leur adaptation à ceux-ci entraînées par des moteurs électriques
F04B 43/12 - "Machines", pompes ou installations de pompage ayant des organes de travail flexibles à action péristaltique
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
42.
Container filling system for radioactive materials
Provided are systems for filling containers with radioactive and/or other types of potentially hazardous materials. In some aspects, the systems include a shielding material that substantially defines a chamber and, preferably, substantially blocks radioactivity, a conduit extending from outside to into the chamber, and a unit that is disposed in the chamber proximal to the conduit and is adapted to receive a capsule through the conduit. The systems of the present disclosure can further comprise a syringe, a syringe controller that is disposed in the dispensing chamber and adapted to meter an aliquot from a radioactive stock solution and inject the aliquot into the capsule or a vial.
The present invention provides a radioisotope generator system with enhanced safety features and implements such system. In particular, the present invention provides a radioisotope generator system comprising a surface that comprises three ports: an evacuation port, a loading port, and a saline flush port. The saline flush port is permanently connected with the loading port so that the rinsing solution can be placed on the saline port and pass it through the Mo-99 vial to minimize the wastage of the Mo-99. The present invention provides a robust design of the three-port radioisotope generator, which is cost-effective and ensures improved safety from needle contamination.
G21G 4/08 - Sources radioactives autres que les sources de neutrons caractérisées par des aspects de leur structure spécialement adaptées aux applications médicales
G21F 5/015 - Récipients blindés portatifs ou transportables pour le stockage de sources radioactives, p. ex. supports de sources pour unités d'irradiationRécipients pour radio-isotopes
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
44.
EXPERT SCORING SYSTEM FOR MEASUREMENT OF SEVERITY, TREATMENT RESPONSE AND PROGNOSIS OF PERIPHERAL ARTERIAL DISEASE
The present invention provides a method of diagnosing and/or treating a peripheral arterial disease (PAD) via Positron Emitting Tomography (PET) imaging technology. The invention provides artificial intelligence dose calculation, infusion or dose monitoring, image analysis, assessment and providing a severity score based on the image analysis and providing suitable therapy options for the subject diagnosed or at a risk of developing peripheral arterial disease.
A61B 6/50 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des parties du corps spécifiquesAppareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des applications cliniques spécifiques
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
G16H 40/67 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement à distance
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
45.
Closed-loop elution system to evaluate patients with suspected or existing peripheral arterial disease
The present invention provides a closed loop generation and/or infusion system comprising a radionuclide generator, an activity detector, a controller, a dose calibrator, a pump, eluant source and an automated elution system controlled by software and hardware for generation and infusion of a radionuclide for administering a dose of generated radionuclide into a subject for diagnosing a peripheral arterial disease in a subject suffering from or suspected of suffering from peripheral arterial disease and/or metabolic disease via Positron Emitting Tomography (PET) or Single-photon emission computed tomography (SPECT) imaging technologies. More particularly, the present invention provides methods of determining whether a subject is suffering or at a risk of developing a peripheral arterial disease by performing quantitative assessment of blood flow in lower extremities or limbs of the subject; wherein the quantitative assessment is performed by analyzing one or more images and providing a severity score; and wherein the analysis of the one or more images is performed by using an automated system.
A61B 6/50 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des parties du corps spécifiquesAppareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des applications cliniques spécifiques
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
The present invention discloses methods for automatically computing an arterial input function from one or more regions of interest, the method comprising: a. obtaining a plurality of dynamic image data sets comprising volumetric image data from the regions of interest over multiple scanning intervals; b. utilizing an artificial neural network to segment the plurality of dynamic image data sets displaying one or more arterial input function(s) (AIF) in the region(s) of interest; c. automatically estimating, using artificial intelligence, an arterial input function based on plurality of dynamic image data sets combined with one or more time activity curves (TAC) in the region(s) of interest in target organ(s); and d. computing a pre-trained predictive pharmacokinetic AI model arterial input function using time activity curve input associated with region(s) of interest of target organ(s).
A radioisotope elution system is provided that has a component in a cabinet with a door equipped with an authentication system to open. The system may also have a user interface equipped with an authentication system. The radioisotope elution system has a dose calibrator equipped with a lifting mechanism for lifting and/or lowering the vial to be tested in the dose calibrator. The lifting mechanism may be controlled for preventing the vial from being lifted during a quality control test on a sample of eluate in the vial. This feature prevents a user from tampering and/or interfering with the vial while a quality control testing is in progress. There also is provided a radioisotope elution system with a scanning system for entering information about the radioisotope generator and/or the patient in the system. Systems ensuring that the eluant reservoir contains a saline solution are proposed.
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
G21F 5/015 - Récipients blindés portatifs ou transportables pour le stockage de sources radioactives, p. ex. supports de sources pour unités d'irradiationRécipients pour radio-isotopes
G21G 4/08 - Sources radioactives autres que les sources de neutrons caractérisées par des aspects de leur structure spécialement adaptées aux applications médicales
48.
IMPROVED AND SAFE TECHNIQUES FOR USE OF RADIOACTIVE GENERATOR
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
49.
IMPROVED AND SAFE TECHNIQUES FOR USE OF RADIOACTIVE GENERATOR
The present invention provides a radioisotope elution system for an improved method for the quality control testing of a radioactive generator. In particular, the present invention relates to a radioisotope elution system and its improved method for quality control testing in order to identify and/or extend the shelf-life of the radioactive generator, wherein the said radioisotope elution system is able to produce an increased amount of radioactive eluate by initiating two or more consecutive elutions at an increased flow rate and/or increased volume of the eluant; and wherein the shelf-life of the radioisotope generator is detected by measuring the enhancement of signal-to-noise ratio towards the end of the generator life.
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
50.
HEAT RESISTANT GENERATOR COLUMNS FOR ELUTION SYSTEMS
The present disclosure relates in general to nuclear medicine and generators for the production of radiopharmaceuticals for medical use. In particular, present disclosure relates to a generator column that resists high heat such as depyrogenation and sterilization. This allows some steps of the preparation of the column to be performed in a non-sterile environment. This also allows the generator column to be reusable. The present disclosure further describes methods for the preparation of a generator where a parent radioisotope is charged on the column matrix before or after the matrix is loaded in the column.
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
G21G 4/08 - Sources radioactives autres que les sources de neutrons caractérisées par des aspects de leur structure spécialement adaptées aux applications médicales
51.
IMAGING METHOD FOR DIAGNOSING CARDIOVASCULAR DISEASE
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
G01R 33/563 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p. ex. angiographie à écoulement contrasté
G01T 1/29 - Mesure effectuée sur des faisceaux de radiations, p. ex. sur la position ou la section du faisceauMesure de la distribution spatiale de radiations
52.
IMAGING METHOD FOR DIAGNOSING CARDIOVASCULAR DISEASE
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
G01R 33/563 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p. ex. angiographie à écoulement contrasté
G01T 1/29 - Mesure effectuée sur des faisceaux de radiations, p. ex. sur la position ou la section du faisceauMesure de la distribution spatiale de radiations
53.
Imaging method for diagnosing cardiovascular disease
1 and TBV parametric maps using artificial neural network;
2 and TBV parametric maps; and of rest and stress myocardial blood flow to estimate myocardial flow reserve (MFR) and/or coronary flow reserve (CFR).
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
A61B 6/50 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des parties du corps spécifiquesAppareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations spécialement adaptés à des applications cliniques spécifiques
G06V 10/25 - Détermination d’une région d’intérêt [ROI] ou d’un volume d’intérêt [VOI]
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
Ottawa Heart Institute Research Corporation (Canada)
Inventeur(s)
Lefort, Etienne
Teoli, Vicenzo
Dekemp, Robert A.
Klein, Ran
Abrégé
Embodiments of the present invention provide for assessing the state of an 82Rb elution system. In certain embodiments, a system begins an assessment that comprises an elution, and a metric may be measured. This metric may be a concentration of 82Rb, 82Sr, or 85Sr in a fluid that is eluted from the generator, the volume of the fluid that is eluted from the generator, or the pressure of the fluid flowing through at least one portion of the system. If the assessment is completed, an output may be generated on a user interface that recommends a course of action, or no course of action, based on a result of the assessment. Should the assessment not complete successfully because it is interrupted, a 82Sr/82Rb generator of the system may be halted so as to prevent a user from performing an end-run around these quality control mechanisms of the 82Rb elution system.
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
99mTc-tetrofosmin radiopharmaceutical composition. It also provides process for the preparation of said radiopharmaceutical compositions and their use in diagnostic imaging procedures. The compositions provide desirable technical attributes such as stability, high radiochemical purity (RCP) and desired bio-distribution.
The present invention relates to a medical radioisotope transport system that securely holds the radiopharmaceutical imaging system or medical elution system to the floor of a vehicle and ensures the protection of the elution system during transportation. The transport system as per the present invention includes at least a floor-mounting device, a support mechanism with transportation plates, and a locking device. The transport system as per the present invention is encompassed with advanced technical and safety features to ensure safe transportation of radiopharmaceuticals ensuring compliance to the regulatory and quality requirements. The transport system as per the present invention is easy to use, and successfully overcome all the complexities involved in prior available methods for transportation of radiopharmaceutical imaging systems or medical radioisotope elution systems.
G21F 5/14 - Dispositifs spécialement adaptés à la manipulation de récipients ou de barils, p. ex. dispositifs de transport
G16H 40/40 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion d’équipement ou de dispositifs médicaux, p. ex. pour planifier la maintenance ou les mises à jour
G16H 40/67 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement à distance
G21F 5/00 - Récipients blindés portatifs ou transportables
G21F 5/015 - Récipients blindés portatifs ou transportables pour le stockage de sources radioactives, p. ex. supports de sources pour unités d'irradiationRécipients pour radio-isotopes
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
57.
Elution protocols and dosages for radiopharmaceutical elution system
A radioisotope elution system is provided. The radioisotope elution system may comprise a controller that is configured to calculate the available amount of daughter radioisotope at any time during establishment of the equilibrium for decay of the parent radioisotope into its daughter radioisotope. The radioisotope elution system may comprise a controller that is configured to schedule various patient infusions planned for the next following days and weeks in accordance with the available amount of daughter radioisotope on each day. The elution system may also comprise a controller that is connected to the imaging software of a radioisotope imaging device, where the radioisotope imaging device is arranged for imaging the patient or a region of the patient; and the controller is configured to start an image acquisition at a predetermined time.
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
58.
Non-invasive stress imaging methods of diagnosing peripheral arterial disease via dynamic pet
The present invention provides a method of determining whether a subject is suffering or at a risk of developing a peripheral arterial disease via Positron Emitting Tomography (PET) imaging technology. The method comprises administering a PET radionuclide into the subject via automated generation and/or infusion system, performing PET scan of the region of interest, automated assessment of the PET images, performing assessment and suggesting the most appropriate therapeutic and/or management options for the patients based on the severity score, provides an assessment of regional lower proximity perfusion and perfusion reserve, and/or regional and mean standardized uptake values (SUVs). More particularly, the method of image processing identifies the regional differences in SMP (Skeletal muscle perfusion) and SMPR (Skeletal muscle perfusion reserve) across calf muscles at rest and cuff-induced hyperemia.
A61B 5/02 - Détection, mesure ou enregistrement en vue de l'évaluation du système cardio-vasculaire, p. ex. mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/0275 - Mesure du débit sanguin utilisant des marqueurs, p. ex. dilution de colorant
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
Present invention relates to safety features for radiopharmaceutical dispensing system, wherein dispensing system comprises a controller, a source of radiopharmaceutical and other components. The controller is configured to perform automated quality control of the system to ensure that the system complies quality control before radioactive dose dispensing. The quality control comprises scanning the dispensing system, network or connected devices for an unauthorized connection, malware and ensure that system is free of any such cybersecurity threat before dispensing a radioactive dose.
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
G06F 21/55 - Détection d’intrusion locale ou mise en œuvre de contre-mesures
62.
RADIOPHARMACEUTICAL GENERATION AND INFUSION SYSTEMS
Provided herein are the safety features for radiopharmaceutical infusion system for treatment or diagnostic purpose, wherein infusion system comprises a controller, a source of radiopharmaceutical including other components. The controller is configured to perform automated quality control steps at the start of the system during daily quality control and ensure that system complies to desired technical attributes prior to administration to patients. The quality control steps comprise calibration, breakthrough testing, checking for unauthorized connection and/or malware in the system, network or other connected devices.
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
G06F 21/56 - Détection ou gestion de programmes malveillants, p. ex. dispositions anti-virus
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
G16H 40/40 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion d’équipement ou de dispositifs médicaux, p. ex. pour planifier la maintenance ou les mises à jour
G16H 40/67 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement à distance
The present invention relates to a pharmaceutical cold kit composition comprising a chelating agent linked to somatostatin receptor binding organic moiety, a stabilizer, a buffer, and a caking agent or bulking agent, wherein the composition is free of sequestering agent. Further, the present invention also relates to the process of preparing reconstituted or radiolabeled solution composition having high in use stability and radiochemical purity and use thereof for diagnostic and/or therapeutic purposes.
The present disclosure relates in general to nuclear medicine and generators for the production of radiopharmaceuticals for medical use. In particular, present disclosure relates to a generator column that resists high heat such as depyrogenation and sterilization. This allows some steps of the preparation of the column to be performed in a non-sterile environment. This also allows the generator column to be reusable. The present disclosure further describes methods for the preparation of a generator where a parent radioisotope is charged on the column matrix before or after the matrix is loaded in the column.
G21G 4/06 - Sources radioactives autres que les sources de neutrons caractérisées par des aspects de leur structure
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
A61L 2/20 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des substances chimiques des substances gazeuses, p. ex. des vapeurs
65.
NON-INVASIVE IMAGING METHODS OF DIAGNOSING PERIPHERAL ARTERIAL DISEASE
The present invention provides a method of determining whether a subject is suffering or at a risk of developing a peripheral arterial disease via Positron Emitting Tomography (PET) imaging technology. The method comprises administering a PET radionuclide into the subject via automated generation and/or infusion system, performing PET scan of the region of interest, automated assessment of the PET images, performing assessment and suggesting the most appropriate therapeutic and/or management options for the patients based on the severity score. The patient can be concurrently suffering from one or more disease like diabetes mellitus.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61K 33/14 - Chlorures des métaux alcalinsChlorures des métaux alcalino-terreux
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
G05B 19/04 - Commande à programme autre que la commande numérique, c.-à-d. dans des automatismes à séquence ou dans des automates à logique
The present invention provides a closed loop generation and/or infusion system comprising a radionuclide generator, an activity detector, a controller, a dose calibrator, a pump, eluant source and an automated elution system controlled by software and hardware for generation and infusion of a radionuclide for administering a dose of generated radionuclide into a subject for diagnosing a peripheral arterial disease in a subject suffering from or suspected of suffering from peripheral arterial disease and/or metabolic disease via Positron Emitting Tomography (PET) or Single-photon emission computed tomography (SPECT) imaging technologies. More particularly, the present invention provides methods of determining whether a subject is suffering or at a risk of developing a peripheral arterial disease by performing quantitative assessment of blood flow in lower extremities or limbs of the subject; wherein the quantitative assessment is performed by analyzing one or more images and providing a severity score; and wherein the analysis of the one or more images is performed by using an automated system.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61K 33/14 - Chlorures des métaux alcalinsChlorures des métaux alcalino-terreux
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
G05B 19/04 - Commande à programme autre que la commande numérique, c.-à-d. dans des automatismes à séquence ou dans des automates à logique
viavia Positron Emitting Tomography (PET) imaging technology. The invention provides artificial intelligence dose calculation, infusion or dose monitoring, image analysis, assessment and providing a severity score based on the image analysis and providing suitable therapy options for the subject diagnosed or at a risk of developing peripheral arterial disease.
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
68.
EXPERT SCORING SYSTEM FOR MEASUREMENT OF SEVERITY, TREATMENT RESPONSE AND PROGNOSIS OF PERIPHERAL ARTERIAL DISEASE
The present invention provides a method of diagnosing and/or treating a peripheral arterial disease (PAD) via Positron Emitting Tomography (PET) imaging technology. The invention provides artificial intelligence dose calculation, infusion or dose monitoring, image analysis, assessment and providing a severity score based on the image analysis and providing suitable therapy options for the subject diagnosed or at a risk of developing peripheral arterial disease.
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
69.
CLOSED-LOOP ELUTION SYSTEM TO EVALUATE PATIENTS WITH SUSPECTED OR EXISTING PERIPHERAL ARTERIAL DISEASE
viavia Positron Emitting Tomography (PET) or Single-photon emission computed tomography (SPECT) imaging technologies. More particularly, the present invention provides methods of determining whether a subject is suffering or at a risk of developing a peripheral arterial disease by performing quantitative assessment of blood flow in lower extremities or limbs of the subject; wherein the quantitative assessment is performed by analyzing one or more images and providing a severity score; and wherein the analysis of the one or more images is performed by using an automated system.
G05B 19/04 - Commande à programme autre que la commande numérique, c.-à-d. dans des automatismes à séquence ou dans des automates à logique
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
70.
NON-INVASIVE IMAGING METHODS OF DIAGNOSING PERIPHERAL ARTERIAL DISEASE
viaviavia automated generation and/or infusion system, performing PET scan of the region of interest, automated assessment of the PET images, performing assessment and suggesting the most appropriate therapeutic and/or management options for the patients based on the severity score. The patient can be concurrently suffering from one or more disease like diabetes mellitus.
G05B 19/04 - Commande à programme autre que la commande numérique, c.-à-d. dans des automatismes à séquence ou dans des automates à logique
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
Ottawa Heart Institute Research Corporation (Canada)
Inventeur(s)
Lefort, Etienne
Teoli, Vincenzo
Dekemp, Robert A.
Klein, Ran
Abrégé
Provided are 82Sr/82Rb elution systems that accept patient weight as a input function in order to determine an optimal quantity of radioactive rubidium-82 for delivery to a patient pursuant to an imaging scan. Also disclosed are systems that deliver a saline flush to remove residual 82Rb from the system downstream of the generator, and preferably deliver the removed residual 82Rb to the patient. Other disclosed systems measure the total volume of saline that flows through a 82Sr/82Rb generator, a total volume of saline that flows through the generator and through a bypass line, or a total volume of saline received by a waste reservoir, in order to monitor system components so that optimal system functioning is assured.
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
G16H 20/40 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des thérapies mécaniques, la radiothérapie ou des thérapies invasives, p. ex. la chirurgie, la thérapie laser, la dialyse ou l’acuponcture
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
A61M 5/14 - Dispositifs de perfusion, p. ex. perfusion par gravitéPerfusion sanguineAccessoires à cet effet
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p. ex. compteurs de goutte-à-goutte
72.
RADIOPHARMACEUTICAL COMPOSITIONS OF RADIOACTIVE HALOGENATED BENZYLGUANIDINE
The present disclosure concerns radiopharmaceutical compositions of radioactive halogenated benzylguanidine (such as radioiodinated MIBG) or a pharmaceutically acceptable salt, hydrate, or solvate thereof. In a preferred embodiment, the composition has at least 97% of radiochemical purity for at least 4 days. Advantageously, the compositions of the present disclosure may be devoid of parabens, which are carcinogenic and yet are used in known radioactive MIBG compositions. The present disclosure also provides processes of preparing a radioactive halogenated benzylguanidine composition. The compositions of the present disclosure can be used in diagnosis and treatment of various diseases.
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Education services, namely, providing training, workshops,
courses, and instruction in the generation, administration,
and storage of radioisotopes for medical diagnostic use.
Elution apparatus for generating, calibrating, dispensing,
and storing radioisotopes for medical diagnostic use, and
parts and fittings therefor; elution apparatus for infusing
and monitoring infusions of radioisotope to patients for
medical diagnostic use; medical equipment, namely, tubing
lines for use in an elution apparatus which generates,
calibrates, dispenses, and stores radioisotopes for medical
diagnostic use.
Elution apparatus for generating, calibrating, dispensing,
and storing radioisotopes for medical diagnostic use, and
parts and fittings therefor; elution apparatus for infusing
and monitoring infusions of radioisotope to patients for
medical diagnostic use; medical equipment, namely, tubing
lines for use in an elution apparatus which generates,
calibrates, dispenses, and stores radioisotopes for medical
diagnostic use.
Elution apparatus for generating, calibrating, dispensing,
and storing radioisotopes for medical diagnostic use, and
parts and fittings therefor; portable generator with
variable radioisotopes and activity for use in an elution
apparatus.
Elution apparatus for generating, calibrating, dispensing,
and storing radioisotopes for medical diagnostic use, and
parts and fittings therefor; elution apparatus for infusing
and monitoring infusions of radioisotope to patients for
medical diagnostic use; medical equipment, namely, tubing
lines for use in an elution apparatus which generates,
calibrates, dispenses, and stores radioisotopes for medical
diagnostic use.
78.
CONTAINER FILLING SYSTEM FOR RADIOACTIVE MATERIALS
Provided are systems for filling containers with radioactive and/or other types of potentially hazardous materials. In some aspects, the systems include a shielding material that substantially defines a chamber and, preferably, substantially blocks radioactivity, a conduit extending from outside to into the chamber, and a unit that is disposed in the chamber proximal to the conduit and is adapted to receive a capsule through the conduit. The systems of the present disclosure can further comprise a syringe, a syringe controller that is disposed in the dispensing chamber and adapted to meter an aliquot from a radioactive stock solution and inject the aliquot into the capsule or a vial.
Provided are systems for filling containers with radioactive and/or other types of potentially hazardous materials. In some aspects, the systems include a shielding material that substantially defines a chamber and, preferably, substantially blocks radioactivity, a conduit extending from outside to into the chamber, and a unit that is disposed in the chamber proximal to the conduit and is adapted to receive a capsule through the conduit. The systems of the present disclosure can further comprise a syringe, a syringe controller that is disposed in the dispensing chamber and adapted to meter an aliquot from a radioactive stock solution and inject the aliquot into the capsule or a vial.
Shielded filling cell for storage, preparation and transferring radioactive iodide solutions to capsules and vials, namely, medical apparatus for the storage, preparation and transferring radioactive iodide solutions to capsules and vials
Elution apparatus for generating, calibrating, dispensing,
and storing radioisotopes for medical diagnostic use, and
parts and fittings therefor; elution apparatus for infusing
and monitoring infusions of radioisotope to patients for
medical diagnostic use.
Elution apparatus for generating, calibrating, dispensing,
and storing radioisotopes for medical diagnostic use, and
parts and fittings therefor; elution apparatus for infusing
and monitoring infusions of radioisotope to patients for
medical diagnostic use; medical equipment, namely, tubing
connectors to link tubing lines for use with an elution
apparatus which apparatus generates, calibrates, dispenses,
and stores radioisotopes for medical diagnostic use.
medical apparatus and instrument for diagnostic use, namely, elution medical apparatus for generating, calibrating, dispensing, and storing radioisotopes, and parts and fittings therefor, for medical diagnostic use; medical apparatus and instrument for diagnostic use, namely, elution apparatus for infusing and monitoring infusions of radioisotope to patients for medical diagnostic use; medical equipment, namely, medical tubing lines for use with an elution apparatus which apparatus generates, calibrates, dispenses, and stores radioisotopes for medical diagnostic use
medical apparatus and instrument for diagnostic use, namely, elution medical apparatus for generating, calibrating, dispensing, and storing radioisotopes, and parts and fittings therefor, for medical diagnostic use; medical apparatus and instrument for diagnostic use, namely, elution apparatus for infusing and monitoring infusions of radioisotope to patients for medical diagnostic use; medical equipment, namely, medical tubing lines for use with an elution apparatus which apparatus generates, calibrates, dispenses, and stores radioisotopes for medical diagnostic use
medical apparatus and instrument for diagnostic use, namely, elution medical apparatus for generating, calibrating, dispensing, and storing radioisotopes, and parts and fittings therefor, for medical diagnostic use; medical apparatus and instrument for diagnostic use, namely, elution apparatus for infusing and monitoring infusions of radioisotope to patients for medical diagnostic use; medical equipment, namely, medical tubing lines for use with an elution apparatus which apparatus generates, calibrates, dispenses, and stores radioisotopes for medical diagnostic use
medical apparatus and instrument for diagnostic use, namely, elution medical apparatus for generating, calibrating, dispensing, and storing radioisotopes, and parts and fittings therefor, for medical diagnostic use; medical apparatus and instrument for diagnostic use, namely, elution apparatus for infusing and monitoring infusions of radioisotope to patients for medical diagnostic use
medical apparatus and instrument for diagnostic use, namely, elution medical apparatus for generating, calibrating, dispensing, and storing radioisotopes, and parts and fittings therefor, for medical diagnostic use; medical apparatus and instrument for diagnostic use, namely, elution apparatus for infusing and monitoring infusions of radioisotope to patients for medical diagnostic use; medical equipment, namely, medical tubing connectors to link tubing lines for use with an elution apparatus which apparatus generates, calibrates, dispenses, and stores radioisotopes for medical diagnostic use
medical apparatus and instrument for diagnostic use, namely, elution medical apparatus for generating, calibrating, dispensing, and storing radioisotopes, and parts and fittings therefor, for medical diagnostic use; portable pulse generator featuring variable radioisotopes and variable radioisotope medical activity for use with the elution apparatus for medical diagnostic use
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Education services, namely, providing training, workshops, courses, and instruction in the generation, administration, and storage of radioisotopes for medical diagnostic use
(1) Elution apparatus for generating, calibrating, dispensing, and storing radioisotopes for medical diagnostic use, and parts and fittings therefor; elution apparatus for infusing and monitoring infusions of radioisotope to patients for medical diagnostic use.
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
(1) Education services, namely, providing training, workshops, courses, and instruction in the generation, calibration, administration, and storage of radioisotopes for medical diagnostic use
(1) Elution apparatus for generating, calibrating, dispensing, and storing radioisotopes for medical diagnostic use, and parts and fittings therefor; elution apparatus for infusing and monitoring infusions of radioisotope to patients for medical diagnostic use; medical equipment, namely, tubing lines for use in an elution apparatus which apparatus generates, calibrates, dispenses, and stores radioisotopes for medical diagnostic use.
(1) Elution apparatus for generating, calibrating, dispensing, and storing radioisotopes for medical diagnostic use, and parts and fittings therefor; elution apparatus for infusing and monitoring infusions of radioisotope to patients for medical diagnostic use; medical equipment, namely, tubing lines for use with an elution apparatus which apparatus generates, calibrates, dispenses, and stores radioisotopes for medical diagnostic use.
(1) Elution apparatus for generating, calibrating, dispensing, and storing radioisotopes for medical diagnostic use, and parts and fittings therefor; elution apparatus for infusing and monitoring infusions of radioisotope to patients for medical diagnostic use; medical equipment, namely, tubing lines for use with an elution apparatus which apparatus generates, calibrates, dispenses, and stores radioisotopes for medical diagnostic use.
(1) Elution apparatus for generating, calibrating, dispensing, and storing radioisotopes for medical diagnostic use, and parts and fittings therefor; elution apparatus for infusing and monitoring infusions of radioisotope to patients for medical diagnostic use; medical equipment, namely, tubing connectors to link tubing lines for use with an elution apparatus which apparatus generates, calibrates, dispenses, and stores radioisotopes for medical diagnostic use.
(1) Elution apparatus for generating, calibrating, dispensing, and storing radioisotopes for medical diagnostic use, and parts and fittings therefor; generator of radioisotopes for use in an elution apparatus.
98.
Pharmaceutical compositions of sulfur colloid and processes thereof
99mmTc-Sulfur colloid radiopharmaceutical composition. Further, the process for preparation of said compositions and their use for diagnostic purposes are also disclosed.
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
